Allogene Therapeutics announced that its CFO Eric Schmidt, Ph.D., will step down from his position to spend more time with his family on the East Coast. The Company has initiated a search to fill this position. Dr. Schmidt will remain with the Company through August 2, 2023 to support the reporting of second quarter financials and ensure an orderly transition.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALLO:
- Allogene Therapeutics Announces Departure of Chief Financial Officer
- Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
- Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
- Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress